Ocular Therapeutix (OCUL) Q4 2024 Annual Earnings
OCUL·Reported March 3, 2025·Before market open
Ocular Therapeutix reported Q4 2024 revenue of $17.1M, missed analyst consensus of $17.1M by $29.8K. Diluted EPS came in at $-0.29, missed the $-0.24 consensus by $0.05.
Revenue
$17.1Mmissed by $29.8K
Consensus: $17.1MDiluted EPS
$-0.29missed by $0.05
Consensus: $-0.24
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Ocular Therapeutix's Q4 2024 earnings report.
Ocular Therapeutix (OCUL) reported Q4 2024 earnings on March 3, 2025 before market open.
Ocular Therapeutix reported revenue of $17.1M and diluted EPS of $-0.29 for Q4 2024.
Revenue missed the consensus estimate of $17.1M by $29.8K. EPS missed the consensus estimate of $-0.24 by $0.05.
You can read the 10-K periodic report (0001558370-25-002000) directly on SEC EDGAR. The filing index links above go to sec.gov.